Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRROR fluorescent-guided surgery study in high-grade glioma
NL-OMON60126Phase 1Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2023
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cetuximab-IRDye 800CW and 5-aminolevulinic acid in glioblastoma (GBM) and glioma, sponsored by University Medical Center Groningen. Started Mar 2023; status: recruiting.
02
Drugs
cetuximab-IRDye 800CW5-aminolevulinic acid
03
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on NL-OMON60126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60126.